LOGIN  |  REGISTER
Amneal Pharmaceuticals
Compass Therapeutics

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

August 05, 2024 | Last Trade: US$2.28 0.10 -4.20

AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson.

We are profoundly saddened by the passing of our dear friend and colleague, Sandy Robertson. Sandy served on the Board of Directors of Cassava Sciences since its inception as a public company in 1998. Sandy's commitment to Cassava’s mission and success was unwavering. Sandy’s success in the business world is well recognized by the hundreds of companies that he helped build and the entrepreneurs who created those companies. Everyone who knew or worked alongside Sandy understood his powerful intelligence as well as his remarkable kindness. His success in business was legendary but what those who knew him will remember was who he was: Sandy was the personification of someone who would treat others as he would like to be treated. We will miss him terribly as will anyone who knew him.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com  

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450, or This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page